Dexcom Phasing Out G6 System
May 18, 2026
Dexcom, Inc. announced the planned discontinuation of the Dexcom G6 Continuous Glucose Monitoring (CGM) System effective July 1, 2026.
Recall Notices
Huons Initiates Voluntary Recall of Lidocaine and Bupivacaine Injection Products
May 05, 2026
On April 20, 2026, and April 22, 2026, Huons Co. Ltd. initiated voluntary recalls of lidocaine HCl Injection, USP, and bupivacaine HCl in dextrose Injection for all lots.
Select B. Braun Products Recalled
April 10, 2026
On April 6, 2026, B. Braun Medical initiated a voluntary recall of specific batches of sterile water for injection, 70% dextrose injection, 0.9% sodium chloride irrigation and Lactated Ringer’s irrigation.
Select IV Solutions Recalled
March 31, 2026
On March 17, 2026, Fresenius Kabi USA, LLC initiated a voluntary user level recall of select lots of 0.9% Sodium Chloride Injection, USP, 0.45% Sodium Chloride Injection, USP, and 5% Dextrose Injection, USP supplied in single dose freeflex® bags.
Medical Device Correction for Omnipod 5 Pods
March 23, 2026
On March 12, 2026, Insulet Corporation initiated a voluntary medical device correction of certain Omnipod® 5 Pods.
Ipsen Voluntarily Withdraws Tazverik
March 17, 2026
On March 9, 2026, Ipsen initiated a voluntary withdrawal of Tazverik® (tazemetostat) oral tablets from the US market, effective immediately, for all approved indications.
Webcol Alcohol Prep Pads Recalled
March 09, 2026
On March 3, 2026, Cardinal Health issued a voluntary recall of select lots of Webcol™ Large Alcohol Prep Pads
Udenyca Recalled
March 09, 2026
On Feb. 26, 2026, the FDA issued a class I recall for multiple lots of Accord BioPharma’s Udenyca® (pegfilgrastim cbqv) injection, 6mg/0.6mL single dose prefilled syringes.
Urgent Correction Issued for TRUE METRIX Instructions
March 04, 2026
Summary:
On Feb. 6, 2026, Trividia Health initiated an Urgent Medical Device Correction for TRUE METRIX® Blood Glucose Monitoring Systems
One Lot of Adbry Recalled
February 25, 2026
On Feb. 12, 2026, LEO Pharma initiated a voluntary US recall of Adbry® (tralokinumab ldrm) 300 mg/2mL single dose autoinjector.
The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.